Immune monitoring outcomes of patients with stage III/IV melanoma treated with a combination of pembrolizumab and intratumoral plasmid interleukin 12 (pIL-12).

Alain Patrick Algazi; Katy K. Tsai; Michael Rosenblum; Bernard A. Fox; Robert Hans Ingemar Andtbacka; Amy Li; Kathryn Toshimi Takamura; Mary Dwyer; Erica Browning; Reneta Talia; Chris Twitty; Mai H. Le; Sharron Gargosky; Jean S. Campbell; Carmen Ballesteros-Merino; Carlo Bruno Bifulco; Robert Pierce; Adil Daud

doi:10.1200/JCO.2017.35.7_SUPPL.78

Immune monitoring outcomes of patients with stage III/IV melanoma treated with a combination of pembrolizumab and intratumoral plasmid interleukin 12 (pIL-12).

Alain Patrick Algazi
, Katy K. Tsai
, Michael Rosenblum
, Bernard A. Fox
, Robert Hans Ingemar Andtbacka
, Amy Li
, Kathryn Toshimi Takamura
, Mary Dwyer
, Erica Browning
, Reneta Talia
, Chris Twitty
, Mai H. Le
, Sharron Gargosky
, Jean S. Campbell
, Carmen Ballesteros-Merino
, Carlo Bruno Bifulco
, Robert Pierce
, Adil Daud

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	35
DOIs	https://doi.org/10.1200/JCO.2017.35.7_SUPPL.78
State	Published - Mar 1 2017

Disciplines

Medicine and Health Sciences
Oncology

Access to Document

10.1200/JCO.2017.35.7_SUPPL.78License: Unspecified

Cite this

Algazi, A. P., Tsai, K. K., Rosenblum, M., Fox, B. A., Andtbacka, R. H. I., Li, A., Takamura, K. T., Dwyer, M., Browning, E., Talia, R., Twitty, C., Le, M. H., Gargosky, S., Campbell, J. S., Ballesteros-Merino, C., Bifulco, C. B., Pierce, R., & Daud, A. (2017). Immune monitoring outcomes of patients with stage III/IV melanoma treated with a combination of pembrolizumab and intratumoral plasmid interleukin 12 (pIL-12). Journal of Clinical Oncology, 35. https://doi.org/10.1200/JCO.2017.35.7_SUPPL.78

@article{5146928835d941578fe1ef8f68f110fb,

title = "Immune monitoring outcomes of patients with stage III/IV melanoma treated with a combination of pembrolizumab and intratumoral plasmid interleukin 12 (pIL-12).",

author = "Algazi, \{Alain Patrick\} and Tsai, \{Katy K.\} and Michael Rosenblum and Fox, \{Bernard A.\} and Andtbacka, \{Robert Hans Ingemar\} and Amy Li and Takamura, \{Kathryn Toshimi\} and Mary Dwyer and Erica Browning and Reneta Talia and Chris Twitty and Le, \{Mai H.\} and Sharron Gargosky and Campbell, \{Jean S.\} and Carmen Ballesteros-Merino and Bifulco, \{Carlo Bruno\} and Robert Pierce and Adil Daud",

note = "78 Background: Recent publications support the emergence of predictive biomarkers for pembrolizomab in melanoma based on the expression of PD-L1 in the tumor microenvironment (Daud 2016a) or the frequency of PD-1hiCTLA-4hi on CD8+ TIL (Daud 2016b) whereby immunologically inactive tumors show poor response to immune checkpoint inhibition alone.",

year = "2017",

month = mar,

day = "1",

doi = "10.1200/JCO.2017.35.7\_SUPPL.78",

language = "American English",

volume = "35",

journal = "Journal of Clinical Oncology",

}

Algazi, AP, Tsai, KK, Rosenblum, M, Fox, BA, Andtbacka, RHI, Li, A, Takamura, KT, Dwyer, M, Browning, E, Talia, R, Twitty, C, Le, MH, Gargosky, S, Campbell, JS, Ballesteros-Merino, C, Bifulco, CB, Pierce, R & Daud, A 2017, 'Immune monitoring outcomes of patients with stage III/IV melanoma treated with a combination of pembrolizumab and intratumoral plasmid interleukin 12 (pIL-12).', Journal of Clinical Oncology, vol. 35. https://doi.org/10.1200/JCO.2017.35.7_SUPPL.78

TY - JOUR

T1 - Immune monitoring outcomes of patients with stage III/IV melanoma treated with a combination of pembrolizumab and intratumoral plasmid interleukin 12 (pIL-12).

AU - Algazi, Alain Patrick

AU - Tsai, Katy K.

AU - Rosenblum, Michael

AU - Fox, Bernard A.

AU - Andtbacka, Robert Hans Ingemar

AU - Li, Amy

AU - Takamura, Kathryn Toshimi

AU - Dwyer, Mary

AU - Browning, Erica

AU - Talia, Reneta

AU - Twitty, Chris

AU - Le, Mai H.

AU - Gargosky, Sharron

AU - Campbell, Jean S.

AU - Ballesteros-Merino, Carmen

AU - Bifulco, Carlo Bruno

AU - Pierce, Robert

AU - Daud, Adil

N1 - 78 Background: Recent publications support the emergence of predictive biomarkers for pembrolizomab in melanoma based on the expression of PD-L1 in the tumor microenvironment (Daud 2016a) or the frequency of PD-1hiCTLA-4hi on CD8+ TIL (Daud 2016b) whereby immunologically inactive tumors show poor response to immune checkpoint inhibition alone.

PY - 2017/3/1

Y1 - 2017/3/1

UR - https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.7_suppl.78

U2 - 10.1200/JCO.2017.35.7_SUPPL.78

DO - 10.1200/JCO.2017.35.7_SUPPL.78

M3 - Article

VL - 35

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Immune monitoring outcomes of patients with stage III/IV melanoma treated with a combination of pembrolizumab and intratumoral plasmid interleukin 12 (pIL-12).

Disciplines

Access to Document

Other files and links

Cite this